Comment on “How does the Price Regulation Policy Impact on Patient-Nurse Ratios and the Length of Hospital Stays in Japanese Hospitals?”

2015 ◽  
Vol 10 (2) ◽  
pp. 324-325 ◽  
Author(s):  
Ayako Kondo
2006 ◽  
Vol 32 (2-3) ◽  
pp. 175-192 ◽  
Author(s):  
John A. Vernon ◽  
Joseph H. Golec ◽  
W. Keener Hughen

There is a great deal of misinformation surrounding the economics of pharmaceutical importation and price regulation. Among economists, the principles governing the relationships between prices, innovation, and pharmaceutical research and development (R&D) investment are incontrovertible. Unfortunately, faulty, non-economic analyses abound on these fundamental relationships, reinforcing economic illiteracy and leading to unfounded U.S. public policy.Effective public policy debate requires that all parties to the debate be informed and aware of the potential costs and benefits associated with new policies, or changes in existing policies. This has not yet occurred for pharmaceutical importation and price regulation policy. Therefore, the purpose of this paper is to provide a positive (in contrast to a normative) economic analysis of pharmaceutical importation and price regulation.


2021 ◽  
pp. 1-10
Author(s):  
Aidong Zhao ◽  
Jinsheng Huang ◽  
Huub Ploegmakers ◽  
Erwin van der Krabben ◽  
Xianlei Ma

2007 ◽  
Vol 40 (18) ◽  
pp. 52
Author(s):  
BRUCE K. DIXON
Keyword(s):  

2011 ◽  
Vol 4 (5) ◽  
pp. 27
Author(s):  
MARY ELLEN SCHNEIDER

VASA ◽  
2007 ◽  
Vol 36 (1) ◽  
pp. 17-22
Author(s):  
Schulz ◽  
Kesselring ◽  
Seeberger ◽  
Andresen

Background: Patients admitted to hospital for surgery or acute medical illnesses have a high risk for venous thromboembolism (VTE). Today’s widespread use of low molecular weight heparins (LMWH) for VTE prophylaxis is supposed to have reduced VTE rates substantially. However, data concerning the overall effectiveness of LMWH prophylaxis is sparse. Patients and methods: We prospectively studied all patients with symptomatic and objectively confirmed VTE seen in our hospital over a three year period. Event rates in different wards were analysed and compared. VTE prophylaxis with Enoxaparin was given to all patients at risk during their hospital stay. Results: A total of 50 464 inpatients were treated during the study period. 461 examinations were carried out for symptoms suggestive of VTE and yielded 89 positive results in 85 patients. Seventy eight patients were found to have deep vein thrombosis, 7 had pulmonary embolism, and 4 had both deep venous thrombosis and pulmonary embolism. The overall in hospital VTE event rate was 0.17%. The rate decreased during the study period from 0.22 in year one to 0,16 in year two and 0.13 % in year three. It ranged highest in neurologic and trauma patients (0.32%) and lowest (0.08%) in gynecology-obstetrics. Conclusions: With a simple and strictly applied regimen of prophylaxis with LMWH the overall rate of symptomatic VTE was very low in our hospitalized patients. Beside LMWH prophylaxis, shortening hospital stays and substantial improvements in surgical and anasthesia techniques achieved during the last decades probably play an essential role in decreasing VTE rates.


Sign in / Sign up

Export Citation Format

Share Document